Evidence map›Paper›PMID 32707981›Full record

ArticleNanomaterials (Basel, Switzerland)2020

Improving Quality in Nanoparticle-Induced Cytotoxicity Testing by a Tiered Inter-Laboratory Comparison Study.

Inge Nelissen, Andrea Haase, Sergio Anguissola, Louise Rocks, An Jacobs, Hanny Willems, Christian Riebeling, Andreas Luch, Jean-Pascal Piret, Olivier Toussaint and 26 more

Open access · goldAbstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Cytotoxicity of Hybrid Noble Metal-Polymer Composites.BioMed research international · 2022
    Article
  11. Toxicology and Biocompatibility of Nanomaterials.Nanomaterials (Basel, Switzerland) · 2021
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors at 18 institutions in 15 countries.

Inge NelissenHealth Department, Flemish Institute for Technological Research (VITO), Boeretang 200, 2400 Mol, Belgium.ORCID 0000-0002-1248-3463
Andrea HaaseDepartment of Chemicals and Product Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany.
Sergio AnguissolaCentre for BioNano Interactions, University College Dublin (UCD), Belfield, Dublin 4, Ireland.
Louise RocksCentre for BioNano Interactions, University College Dublin (UCD), Belfield, Dublin 4, Ireland.
An JacobsHealth Department, Flemish Institute for Technological Research (VITO), Boeretang 200, 2400 Mol, Belgium.
Hanny WillemsHealth Department, Flemish Institute for Technological Research (VITO), Boeretang 200, 2400 Mol, Belgium.ORCID 0000-0001-9848-1997
Christian RiebelingDepartment of Chemicals and Product Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany.
Andreas LuchDepartment of Chemicals and Product Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany.
Jean-Pascal PiretResearch Unit in Cellular Biology (URBC), Namur Nanosafety Center (NNC), Namur Research Institute for Life Sciences (NARILIS), University of Namur (UNamur), rue de Bruxelles 61, 5000 Namur, Belgium.
Olivier ToussaintResearch Unit in Cellular Biology (URBC), Namur Nanosafety Center (NNC), Namur Research Institute for Life Sciences (NARILIS), University of Namur (UNamur), rue de Bruxelles 61, 5000 Namur, Belgium.
Bénédicte TrouillerExperimental Toxicology Unit, Institut National de l'Environnement Industriel et des Risques (INERIS), Parc Alata, BP2, 60550 Verneuil-en-Halatte, France.ORCID 0000-0003-4367-2870
Ghislaine LacroixExperimental Toxicology Unit, Institut National de l'Environnement Industriel et des Risques (INERIS), Parc Alata, BP2, 60550 Verneuil-en-Halatte, France.ORCID 0000-0002-3260-8526
Arno C GutlebEnvironmental Research and Innovation (ERIN) Department, Luxembourg Institute of Science and Technology (LIST), 41, rue du Brill, L-4422 Belvaux, Luxembourg.ORCID 0000-0001-9725-9112
Servane ContalEnvironmental Research and Innovation (ERIN) Department, Luxembourg Institute of Science and Technology (LIST), 41, rue du Brill, L-4422 Belvaux, Luxembourg.
Silvia DiabatéInstitute of Toxicology and Genetics, Karlsruhe Institute of Technology (KIT), Hermann-von-Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany.ORCID 0000-0001-6702-4769
Carsten WeissInstitute of Toxicology and Genetics, Karlsruhe Institute of Technology (KIT), Hermann-von-Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany.
Tamara Lozano-FernándezBiomedical Research Center (CINBIO), University of Vigo, Campus Lagoas Marcosende, 36310 Vigo, Spain.ORCID 0000-0002-0365-6895
África González-FernándezBiomedical Research Center (CINBIO), University of Vigo, Campus Lagoas Marcosende, 36310 Vigo, Spain.ORCID 0000-0002-9226-4825
Maria DusinskaHealth Effects Laboratory, Department of Environmental Chemistry, Norwegian Institute for Air Research (NILU), Instituttveien 18, 2007 Kjeller, Norway.
Anna HukHealth Effects Laboratory, Department of Environmental Chemistry, Norwegian Institute for Air Research (NILU), Instituttveien 18, 2007 Kjeller, Norway.
Vicki StoneSchool of Life Sciences, Heriot-Watt University (HWU), Riccarton Campus, Edinburgh EH14 4AS, UK.
Nilesh KanaseSchool of Life Sciences, Heriot-Watt University (HWU), Riccarton Campus, Edinburgh EH14 4AS, UK.
Marek NocuńDepartment of Toxicology and Carcinogenesis, Nofer Institute of Occupational Medicine (NIOM), 91-348 Łódź, Poland.
Maciej StępnikDepartment of Toxicology and Carcinogenesis, Nofer Institute of Occupational Medicine (NIOM), 91-348 Łódź, Poland.ORCID 0000-0003-1586-2482
Stefania MeschiniNational Center for Drug Research and Evaluation and National Center of Innovative Technologies for Public Health, Istituto Superiore di Sanità (ISS), Viale Regina Elena, 299 Rome, Italy.
Maria Grazia AmmendoliaNational Center for Drug Research and Evaluation and National Center of Innovative Technologies for Public Health, Istituto Superiore di Sanità (ISS), Viale Regina Elena, 299 Rome, Italy.ORCID 0000-0003-4121-3005
Nastassja LewinskiInstitute for Work and Health (IST), University of Lausanne and University of Geneva, Route de la Corniche 2, 1066 Epalinges-Lausanne, Switzerland.
Michael RiedikerInstitute for Work and Health (IST), University of Lausanne and University of Geneva, Route de la Corniche 2, 1066 Epalinges-Lausanne, Switzerland.ORCID 0000-0002-5268-864X
Marco VenturiniECAMRICERT SRL, European Center for the Sustainable Impact of Nanotechnology (ECSIN), Corso Stati Uniti 4, 35127 Padova, Italy.
Federico BenettiECAMRICERT SRL, European Center for the Sustainable Impact of Nanotechnology (ECSIN), Corso Stati Uniti 4, 35127 Padova, Italy.
Jan TopinkaInstitute of Experimental Medicine (IEM), Czech Academy of Sciences, Videnska 1083, 14220 Prague 4, Czech Republic.
Tana BrzicovaInstitute of Experimental Medicine (IEM), Czech Academy of Sciences, Videnska 1083, 14220 Prague 4, Czech Republic.
Silvia MilaniFaculty of Physics and Center for NanoScience, Ludwig-Maximilians-Universität, Geshwister-Scholl-Platz 1, 80539 Munich, Germany.
Joachim RädlerFaculty of Physics and Center for NanoScience, Ludwig-Maximilians-Universität, Geshwister-Scholl-Platz 1, 80539 Munich, Germany.
Anna SalvatiCentre for BioNano Interactions, University College Dublin (UCD), Belfield, Dublin 4, Ireland.
Kenneth A DawsonCentre for BioNano Interactions, University College Dublin (UCD), Belfield, Dublin 4, Ireland.
University College Dublin · IEFederal Institute for Risk Assessment · DEFlemish Institute for Technological Research · BECenter for NanoScience · DEHeriot-Watt University · GBInstitut national de l'environnement industriel et des risques · FRIstituto Superiore di Sanità · ITKarlsruhe Institute of Technology · DELuxembourg Institute of Science and Technology · LUNofer Institute of Occupational Medicine · PLUniversidade de Vigo · ESUniversity of Geneva · CHUniversity of Namur · BEVeneto Nanotech (Italy) · ITCzech Academy of Sciences, Institute of Experimental Medicine · CZGentian (Norway) · NONILU · NOVSB - Technical University of Ostrava · CZ

Funding

DG06 (Direction générale opérationnelle de l'Economie, de l'Emploi et de la Recherche) of the Walloon Region of Belgium 1117448EC FP7 project QualityNano INFRA-2010-1.1.31-262163Fonds National de la Recherche of Luxembourg, project NANION FNR/12/SR/4009651Norwegian Research Council, NorNANoREG project 239199/070
6 · The paper itself

Abstract

The quality and relevance of nanosafety studies constitute major challenges to ensure their key role as a supporting tool in sustainable innovation, and subsequent competitive economic advantage. However, the number of apparently contradictory and inconclusive research results has increased in the past few years, indicating the need to introduce harmonized protocols and good practices in the nanosafety research community. Therefore, we aimed to evaluate if best-practice training and inter-laboratory comparison (ILC) of performance of the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay for the cytotoxicity assessment of nanomaterials among 15 European laboratories can improve quality in nanosafety testing. We used two well-described model nanoparticles, 40-nm carboxylated polystyrene (PS-COOH) and 50-nm amino-modified polystyrene (PS-NH2). We followed a tiered approach using well-developed standard operating procedures (SOPs) and sharing the same cells, serum and nanoparticles. We started with determination of the cell growth rate (tier 1), followed by a method transfer phase, in which all laboratories performed the first ILC on the MTS assay (tier 2). Based on the outcome of tier 2 and a survey of laboratory practices, specific training was organized, and the MTS assay SOP was refined. This led to largely improved intra- and inter-laboratory reproducibility in tier 3. In addition, we confirmed that PS-COOH and PS-NH2 are suitable negative and positive control nanoparticles, respectively, to evaluate impact of nanomaterials on cell viability using the MTS assay. Overall, we have demonstrated that the tiered process followed here, with the use of SOPs and representative control nanomaterials, is necessary and makes it possible to achieve good inter-laboratory reproducibility, and therefore high-quality nanotoxicological data.

Indexed as

best practicecytotoxicityinter-laboratory comparisonnanosafetytraining

Identifiers

PMID32707981
PMCPMC7466672
OpenAlexW3043864493

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.